2017 BIOSIMILARS AND BIOBETTERS

SMi is proud to present its 8th annual Biosimilars and Biobetters conference which returns to London in September 2017 to reflect on the ongoing issues and latest developments in this rapidly expanding field.

As the patents for several innovator biologics expire, biopharmaceutical companies are taking the opportunity to develop more affordable forms. By the year 2018 more than 30 innovator biologics with sales of $79 billion will have lost their patents* making biosimilars one of the fastest growing markets. This year's event will bring together industry leaders to discuss the latest cases and complexities in the commercialisation and design of biosimilars. We will explore regulatory guidelines and the ways in which interchangeability is likely to shape the market. We will identify challenges to manufacturing, deepen our understanding of clinical trial design, and discuss the topic of pricing.

As the field of biosimilars evolves, challenges in immunogenicity studies and exclusivity still persist. Join us as we address the many pressing issues in this exciting field and hear from regulatory bodies how best to secure approval.